Therapeutic efficacy of dihydroartemisinin–piperaquine for the treatment of uncomplicated Plasmodium vivax malaria in Seacha area, Arbaminch Zuria District, South West Ethiopia
Open Access
- 27 November 2022
- journal article
- research article
- Published by Springer Nature in Malaria Journal
- Vol. 21 (1) , 1-8
Abstract
Declining efficacy of chloroquine against Plasmodium vivax malaria has been documented in Ethiopia. Thus, there is a need to assess the efficacy of alternative schizontocidal anti-malarials such as dihydroartemisinin–piperaquine (DHA–PPQ) in P. vivax malaria-infected patients. This study was conducted to evaluate the therapeutic efficacy of DHA–PPQ drug in South West Ethiopia. This is a single-arm, prospective therapeutic efficacy study in patients with uncomplicated P. vivax malaria. The study was conducted from May 2021 to August 2021, based on the standard World Health Organization study protocol for surveillance of anti-malarial therapeutic efficacy. The study endpoint was adequate clinical and parasitological response on day 42. A total of 86 patients with uncomplicated vivax malaria were enrolled. Of these, 79 patients completed the scheduled follow up; all showing adequate clinical and parasitological responses to day 42, with a successful cure rate of 100% (95% CI 96–100). Parasitaemias were cleared rapidly (86% by day 1 and 100% by day 3), as were clinical symptoms (100% by day 1). Gametocyte carriage decreased from 44% on Day 0 to 1% on day 1 and 0% on Day 2. Mean haemoglobin concentrations increased between day 0 (mean 12.2 g/dL) and day 42 (mean 13.3 g/dL). Treatment was well tolerated and no severe adverse events were observed. In summary, treatment with DHA–PPQ demonstrated excellent efficacy for uncomplicated P. vivax, with no recurrences to day 42, and no safety concerns. This treatment, which is also effective against P. falciparum, appears to be an ideal alternative for P. vivax as part of the malaria elimination programme.Keywords
This publication has 16 references indexed in Scilit:
- Management of relapsingPlasmodium vivaxmalariaExpert Review of Anti-infective Therapy, 2016
- Chloroquine efficacy for Plasmodium vivax malaria treatment in southern EthiopiaMalaria Journal, 2015
- Entomologic Inoculation Rates of Anopheles arabiensis in Southwestern EthiopiaThe American Journal of Tropical Medicine and Hygiene, 2013
- Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Halaba district, South EthiopiaParasites & Vectors, 2011
- Confirmed Vivax Resistance to Chloroquine and Effectiveness of Artemether-Lumefantrine for the Treatment of Vivax Malaria in EthiopiaThe American Journal of Tropical Medicine and Hygiene, 2011
- A Trial of Combination Antimalarial Therapies in Children from Papua New GuineaNew England Journal of Medicine, 2008
- Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, EthiopiaMalaria Journal, 2008
- Chloroquine resistance of Plasmodium falciparum malaria in Ethiopia and EritreaTropical Medicine & International Health, 2007
- Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Malaria: A Randomized TrialPLoS Clinical Trials, 2007
- CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM MALARIA IN ETHIOPIAThe Lancet, 1986